Pazopanib in advanced soft tissue sarcomas.

Loading...
Thumbnail Image

Embargo End Date

Authors

Lee, ATJ
Jones, RL
Huang, PH

Document Type

Journal Article

Date

2019-05-17

Date Accepted

2019-04-16

Abstract

Pazopanib is the first and only tyrosine kinase inhibitor currently approved for the treatment of multiple histological subtypes of soft tissue sarcoma (STS). Initially developed as a small molecule inhibitor of vascular endothelial growth factor receptors, preclinical work indicates that pazopanib exerts an anticancer effect through the inhibition of both angiogenic and oncogenic signaling pathways. Following the establishment of optimal dosing and safety profiles in early phase studies and approval for the treatment of advanced renal cell carcinoma, pazopanib was investigated in STS. A landmark phase III randomized study demonstrated improved progression-free survival with pazopanib compared to that with placebo in pretreated patients with STS of various subtypes. The efficacy of pazopanib in specific STS subtypes has been further described in real-world-based case series in both mixed and subtype-specific STS cohorts. At present, there are no clinically validated predictive biomarkers for use in selecting patients with advanced STS for pazopanib therapy, limiting the clinical effectiveness and cost-effectiveness of the drug. In this review, we summarize the preclinical and clinical data for pazopanib, outline the evidence base for its effect in STS and explore reported studies that have investigated putative biomarkers.

Citation

Signal transduction and targeted therapy, 2019, 4 pp. 16 - ?

Source Title

Publisher

NATURE PUBLISHING GROUP

ISSN

2095-9907

eISSN

2059-3635

Research Team

Sarcoma Clinical Trials (R Jones)
Molecular and Systems Oncology

Notes